Table 3 Relationships between LAG-3 and clinical data
Characteristic | LAG-3 expression on TILs | ||
|---|---|---|---|
 ≤ 14 | > 14 | p value | |
Age, n (%) | |||
 < 60 | 27 (14.8) | 128 (70.3) | 0.137 |
 ≥ 60 | 8 (4.5) | 19 (10.4) |  |
Gender, n (%) | |||
 Female | 15 (8.2) | 35 (19.2) | 0.023 |
 Male | 20 (11) | 112 (61.6) |  |
Smoking status, n (%) | |||
 Non-smoker | 27 (14.8) | 124 (68.1) | 0.308 |
 Smoker | 8 (4.4) | 23 (12.7) |  |
Disease stage, n (%) | |||
 Stage I–II | 7 (3.8) | 37 (20.3) | 0.521 |
 Stage III–IV | 28 (15.5) | 110 (60.4) |  |
Pathological type, n (%) | |||
 I–II | 8 (4.4) | 47 (25.8) | 0.291 |
 III | 27 (14.9) | 100 (54.9) |  |
EBV status, n (%) | |||
 Negative | 23 (7.1) | 44 (29.7) |  < 0.001 |
 Positive | 12 (12.1) | 103 (51.1) |  |
Family history, n (%) | |||
 Yes | 8 (4.4) | 18 (9.9) | 0.107 |
 No | 27 (14.8) | 129 (70.9) |  |
Treatment, n (%) | |||
 Induction chemotherapy | 5 (2.7) | 35(19.2) | 0.213 |
 Radiotherapy | 3 (1.6) | 8 (4.5) |  |
 Radiochemotherapy | 26 (14.3) | 104 (57.2) |  |
 Chemotherapy | 1(0.5) | 0 (0) |  |